(Q53729000)

18 May 2018

editorial

0 references

review article

1 reference

title

Specific allergen immunotherapy: time for alternatives? (English)

1 reference

18 May 2018

1 reference

2

1 reference

18 May 2018

author name string

Douglass J

series ordinal

1

1 reference

18 May 2018

publication date

1 January 2002

1 reference

18 May 2018

Clinical & Experimental Allergy

published in

1 reference

18 May 2018

volume

32

1 reference

18 May 2018

issue

1

1 reference

18 May 2018

page(s)

1-3

1 reference

18 May 2018

Allergen immunotherapy: current and new therapeutic strategies

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Systemic reactions and fatalities associated with allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Food for thought: can immunological tolerance be induced to treat asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Nasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: implications for clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0022-0477.2001.01278.X

10.1046/J.0022-0477.2001.01278.X

21 January 2018

Identifiers

DOI

1 reference

18 May 2018

1 reference

18 May 2018